Nephrocare Health Services reported FY26 revenue of ₹998.8 crore, up 32.2% YoY, driven by 16.6% treatment growth and international expansion.
Adjusted EBITDA increased 37.6% to ₹238.1 crore with margins expanding 100 bps to 23.8%, while adjusted PAT surged 74.6% to ₹128.3 crore.
International revenue contribution rose to 41.8% from 31.8% in FY25, improving revenue per treatment by 13.3% and driving ROCE to 22.8%.
The company operates 520+ dialysis centers across India, Nepal, Philippines, Uzbekistan, and Saudi Arabia with 36,981 patients as of March 2026.